Idera Pharmaceuticals (AMEX: IDP) today announced that it had presented preclinical data for its TLR9 agonists in mouse lung cancer models at the...
Three Presentations at American Association of Immunologists Meeting ? Idera Pharmaceuticals (AMEX: IDP) today announced that it has expanded...
Idera Pharmaceuticals (AMEX: IDP) today announced two company presentations to take place during the Biotechnology Industry Organization 2006...
Idera Pharmaceuticals, Inc. (AMEX: IDP) announced today that it has raised $9.75 million in gross proceeds from the private placement of common...
Idera Pharmaceuticals, Inc. (AMEX: IDP) announced today that Sudhir Agrawal, D. Phil., Idera's Chief Executive Officer and Chief Scientific...
CAMBRIDGE, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Idera Pharmaceuticals, Inc. (AMEX:IDP) announced today that Timothy Sullivan, Ph.D., Vice...
Study to be Conducted at Georgetown University Medical Center Includes Phase 2 Component in First-Line Non-Small Cell Lung Cancer CAMBRIDGE...
Amendment to Accommodate Increased Enrollment of Treatment-Naive Patients CAMBRIDGE, Mass., Oct. 20 /PRNewswire-FirstCall/ -- Idera...
CAMBRIDGE, Mass., Oct. 18 /PRNewswire-FirstCall/ -- Idera Pharmaceuticals, Inc. (AMEX:IDP) announced today that Sudhir Agrawal, D. Phil, Chief...
Idera is Developing Targeted Immune Therapies Based on Toll-like Receptors CAMBRIDGE, Mass., Sept. 12 /PRNewswire-FirstCall/ -- Hybridon, Inc...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.